Large-scale testing (Phase 3)Study completedNCT00150202What this trial is testingClinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)Who this might be right forMacular Degeneration Pfizer 90
Large-scale testing (Phase 3)Study completedNCT03844074What this trial is testingA Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Who this might be right forAge-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration Outlook Therapeutics, Inc. 61
Large-scale testing (Phase 3)Study completedNCT04005352What this trial is testingStudy to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)Who this might be right forAge-related Macular Degeneration Novartis Pharmaceuticals 734
Large-scale testing (Phase 3)Study completedNCT00826371What this trial is testingEvaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) PatientsWho this might be right forAge Related Macular Degeneration Novartis Pharmaceuticals 114
Large-scale testing (Phase 3)Study completedNCT03834753What this trial is testingA Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)Who this might be right forAge-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration Outlook Therapeutics, Inc. 228
Testing effectiveness (Phase 2)Study completedNCT00138632What this trial is testingSafety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)Who this might be right forWet Age-Related Macular Degeneration Novartis 50
Post-approval studies (Phase 4)Study completedNCT04679935What this trial is testingEfficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationWho this might be right forAge-related Macular Degeneration Novartis Pharmaceuticals 52
Early research (Phase 1)Study completedNCT00503022What this trial is testingSafety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular DegenerationWho this might be right forWet Age-Related Macular Degeneration Novartis 20
Testing effectiveness (Phase 2)Study completedNCT00239928What this trial is testingClinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular DegenerationWho this might be right forMacular Degeneration Pfizer 61
Post-approval studies (Phase 4)Study completedNCT01972789What this trial is testingComparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)Who this might be right forSubfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD Novartis Pharmaceuticals 349
Large-scale testing (Phase 3)Study completedNCT00090623What this trial is testingRhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)Who this might be right forMacular Degeneration Genentech, Inc. 180
Large-scale testing (Phase 3)Study completedNCT04597632What this trial is testingAn Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyWho this might be right forNeovascular Age-related Macular Degeneration Novartis Pharmaceuticals 248
Post-approval studies (Phase 4)Study completedNCT05269966What this trial is testingStudy to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)Who this might be right forNeovascular Age-related Macular Degeneration (nAMD) Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)Ended earlyNCT02228304What this trial is testingStudy of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)Who this might be right forMacular Degeneration Neurotech Pharmaceuticals 42